DE602004015614D1 - 2- (chinoxalin-5-ylsulfonylamino) -benzamidverbindungen als cck2-modulatoren - Google Patents

2- (chinoxalin-5-ylsulfonylamino) -benzamidverbindungen als cck2-modulatoren

Info

Publication number
DE602004015614D1
DE602004015614D1 DE602004015614T DE602004015614T DE602004015614D1 DE 602004015614 D1 DE602004015614 D1 DE 602004015614D1 DE 602004015614 T DE602004015614 T DE 602004015614T DE 602004015614 T DE602004015614 T DE 602004015614T DE 602004015614 D1 DE602004015614 D1 DE 602004015614D1
Authority
DE
Germany
Prior art keywords
chinoxalin
ylsulfonylamino
benzamide compounds
cck2
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004015614T
Other languages
English (en)
Inventor
Brett D Allison
Michael D Hack
Victor K Phuong
Michael H Rabinowitz
Mark D Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE602004015614D1 publication Critical patent/DE602004015614D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/42Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
DE602004015614T 2003-08-08 2004-08-04 2- (chinoxalin-5-ylsulfonylamino) -benzamidverbindungen als cck2-modulatoren Active DE602004015614D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49407403P 2003-08-08 2003-08-08
PCT/US2004/025153 WO2005016896A1 (en) 2003-08-08 2004-08-04 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators

Publications (1)

Publication Number Publication Date
DE602004015614D1 true DE602004015614D1 (de) 2008-09-18

Family

ID=34193199

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004015614T Active DE602004015614D1 (de) 2003-08-08 2004-08-04 2- (chinoxalin-5-ylsulfonylamino) -benzamidverbindungen als cck2-modulatoren
DE602004004663T Active DE602004004663T2 (de) 2003-08-08 2004-08-04 Verfahren zur herstellung von 2- (chinoxalin-5-ylsulfonylamino) -benzamid-verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004004663T Active DE602004004663T2 (de) 2003-08-08 2004-08-04 Verfahren zur herstellung von 2- (chinoxalin-5-ylsulfonylamino) -benzamid-verbindungen

Country Status (33)

Country Link
US (3) US7288651B2 (de)
EP (2) EP1651622B1 (de)
JP (2) JP4818110B2 (de)
KR (1) KR20060060007A (de)
CN (2) CN1863781A (de)
AR (1) AR045930A1 (de)
AT (2) ATE353322T1 (de)
AU (2) AU2004265312B2 (de)
BR (1) BRPI0413449A (de)
CA (2) CA2534887A1 (de)
CR (1) CR8229A (de)
CY (1) CY1106486T1 (de)
DE (2) DE602004015614D1 (de)
DK (2) DK1651622T3 (de)
EA (1) EA200600203A1 (de)
EC (1) ECSP066355A (de)
ES (2) ES2281834T3 (de)
HR (1) HRP20080559T3 (de)
IL (1) IL173591A0 (de)
IS (1) IS8280A (de)
LT (1) LT5410B (de)
LV (1) LV13453B (de)
MX (2) MXPA06001550A (de)
NO (1) NO20061122L (de)
NZ (1) NZ545030A (de)
PL (2) PL1651622T3 (de)
PT (2) PT1651621E (de)
SG (1) SG131114A1 (de)
SI (2) SI1651621T1 (de)
TW (1) TW200521120A (de)
UA (1) UA84025C2 (de)
WO (2) WO2005016896A1 (de)
ZA (1) ZA200601946B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1651621E (pt) * 2003-08-08 2008-09-30 Janssen Pharmaceutica Nv Compostos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de cck2
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
US7947833B2 (en) * 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
BRPI0516027A (pt) 2004-09-24 2008-08-19 Janssen Pharmaceutica Nv compostos de sulfonamida
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) * 2007-01-12 2013-11-26 The Board Of Trustees Of The Leland Stanford Junior University Preparation of azide-modified carbon surfaces for coupling to various species
JP5497429B2 (ja) * 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
WO2008124518A1 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131245A3 (de) * 2008-06-02 2012-08-01 ASML Netherlands BV Lithografische Vorrichtung und deren Fokusbestimmungsverfahren
US8354557B2 (en) * 2008-06-17 2013-01-15 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
US20100305093A1 (en) * 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
US9115132B2 (en) 2010-07-09 2015-08-25 Convergence Pharmaceuticals Limited Tetrazole compounds as calcium channel blockers
KR20130043207A (ko) 2010-07-22 2013-04-29 자프겐 인크. 트리시클릭 화합물 및 이의 제조 및 사용 방법
JP6058557B2 (ja) 2011-01-26 2017-01-11 ザフゲン,インコーポレイテッド テトラゾール化合物ならびにその作製方法および使用方法
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン,インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
EP2804856B1 (de) 2012-01-18 2017-03-15 Zafgen, Inc. Tricyclische sulfonverbindungen sowie verfahren zur herstellung und verwendung davon
HUE038700T2 (hu) 2012-03-01 2018-11-28 Allergan Inc Benzofuran-2-szulfonamid származékok, mint kemokinreceptor-modulációk
CN104918615B (zh) 2012-11-05 2018-10-12 扎夫根股份有限公司 治疗肝病的方法
EP2925737B1 (de) 2012-11-05 2017-06-14 Zafgen, Inc. Tricyclische verbindungen zur verwendung bei der behandlung und/oder kontrolle von adipositas
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) * 2013-10-24 2016-05-18 江苏鼎龙科技有限公司 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
BR112016011727A2 (pt) 2013-11-22 2017-08-08 CL BioSciences LLC Antagonistas de gastrina para o tratamento e prevenção de osteoporose
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN106565509A (zh) * 2016-11-03 2017-04-19 江苏鼎龙科技有限公司 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko) 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108218806B (zh) * 2018-04-02 2019-03-01 上海馨远医药科技有限公司 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200420D0 (en) 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
HU222178B1 (hu) 1993-08-10 2003-04-28 James Black Foundation Ltd. Gasztrin és CCK-receptor ligandumok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények
AU721081B2 (en) 1996-12-10 2000-06-22 Zeria Pharmaceutical Co., Ltd. 1,5-benzodiazepine derivatives
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
ITTO20020674A1 (it) * 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) * 2002-11-14 2005-09-13 Bristol-Myers Squibb Company N-cycloalkylglycines as HIV protease inhibitors
PT1651621E (pt) * 2003-08-08 2008-09-30 Janssen Pharmaceutica Nv Compostos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de cck2
BRPI0516027A (pt) * 2004-09-24 2008-08-19 Janssen Pharmaceutica Nv compostos de sulfonamida

Also Published As

Publication number Publication date
MXPA06001550A (es) 2006-09-04
ES2310294T3 (es) 2009-01-01
PT1651621E (pt) 2008-09-30
CA2534887A1 (en) 2005-02-24
LT2006017A (en) 2006-11-27
US20050038032A1 (en) 2005-02-17
WO2005016896A1 (en) 2005-02-24
DK1651621T3 (da) 2008-11-10
US7563895B2 (en) 2009-07-21
EA200600203A1 (ru) 2006-08-25
AR045930A1 (es) 2005-11-16
MXPA06001482A (es) 2006-09-04
EP1651621A1 (de) 2006-05-03
CN1863782A (zh) 2006-11-15
JP2007501842A (ja) 2007-02-01
IS8280A (is) 2006-01-31
JP4818110B2 (ja) 2011-11-16
KR20060060007A (ko) 2006-06-02
EP1651622B1 (de) 2007-02-07
ATE353322T1 (de) 2007-02-15
NZ545030A (en) 2009-08-28
AU2004265312B2 (en) 2010-05-20
UA84025C2 (en) 2008-09-10
ZA200601946B (en) 2007-05-30
DE602004004663D1 (de) 2007-03-22
US7288651B2 (en) 2007-10-30
PT1651622E (pt) 2007-04-30
SI1651622T1 (sl) 2007-06-30
CY1106486T1 (el) 2012-01-25
PL1651621T3 (pl) 2009-01-30
AU2004265312A1 (en) 2005-02-24
US7304051B2 (en) 2007-12-04
IL173591A0 (en) 2006-07-05
CR8229A (es) 2008-09-10
LV13453B (en) 2007-02-20
EP1651621B1 (de) 2008-08-06
CA2534885C (en) 2013-06-04
SG131114A1 (en) 2007-04-26
CN1863781A (zh) 2006-11-15
WO2005016897A1 (en) 2005-02-24
SI1651621T1 (sl) 2008-12-31
LT5410B (lt) 2007-03-26
DE602004004663T2 (de) 2007-11-22
JP2007501841A (ja) 2007-02-01
NO20061122L (no) 2006-05-04
AU2004265311A1 (en) 2005-02-24
ES2281834T3 (es) 2007-10-01
US20080076918A1 (en) 2008-03-27
EP1651622A1 (de) 2006-05-03
US20050043310A1 (en) 2005-02-24
ECSP066355A (es) 2006-08-30
BRPI0413449A (pt) 2006-10-17
HRP20080559T3 (en) 2009-01-31
TW200521120A (en) 2005-07-01
PL1651622T3 (pl) 2007-07-31
ATE403650T1 (de) 2008-08-15
CA2534885A1 (en) 2005-02-24
DK1651622T3 (da) 2007-05-07

Similar Documents

Publication Publication Date Title
ATE403650T1 (de) 2- (chinoxalin-5-ylsulfonylamino) - benzamidverbindungen als cck2-modulatoren
NO20054005D0 (no) Nye arylpiperazinylforbindelser
SE0302305D0 (sv) Novel Compounds
IS2761B (is) Ný amínóbensófenónefnasambönd
ECSP066436A (es) Compuestos heterociclicos fusionados
IS8108A (is) Ný efnasambönd
NO20054310D0 (no) Polyetylenglykolbundede GLP-1-forbindelser
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
NO20052928D0 (no) Nye kjemiske forbindelser
IS7471A (is) Ný efnasambönd
IS8228A (is) Ný asetídínefnasambönd
IS7827A (is) Ný efnasambönd
IS8292A (is) Ný efnasambönd
NO20055750D0 (no) Nye kjemiske forbindelser
DE602004006997D1 (de) 4-(aminomethyl)-piperidinbenzamide als 5ht4 -antagonisten
SE0303452D0 (sv) New compounds
SE0203348D0 (sv) Novel compounds
SE0300118D0 (sv) Novel Compounds
SE0300388D0 (sv) Novel compounds
SE0302667D0 (sv) Novel Compounds
SE0200117D0 (sv) Novel compounds
SE0200118D0 (sv) Novel compounds
SE0201636D0 (sv) Novel compounds
SE0201857D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition